SCHEMBL2511779

SCHEMBL2511779

O=C(Cc1ccc(Nc2c(Cl)cc(C(F)(F)F)cc2Cl)cc1)NCCO

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.43
BACE1 P56817 2/20 0.42
BACE2 Q9Y5Z0 1/20 0.42
NLRP3 Q96P20 1/20 0.42
TACR1 P25103 1/20 0.42
LTA4H P09960 1/20 0.41
EPHX2 P34913 1/20 0.41
CDK1 P06493 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
LMNA P02545 1/20 0.40
CNR2 P34972 1/20 0.39
RORC P51449 1/20 0.39
RHOC P08134 2/20 0.39
RHOA P61586 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CNR1 P21554 1/20 0.39
TRPV1 Q8NER1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578847 0.86 HPGD (0.46) NLRP3LTA4HEPHX2LMNACNR2
SCHEMBL1578838 0.85 EPHX2 (0.47) NLRP3LTA4HEPHX2RORCCNR1
SCHEMBL1578491 0.84 LMNA (0.40) GLACDK1MRGPRX4LMNARHOC
SCHEMBL1578717 0.84 BACE1 (0.41) GLABACE1BACE2NLRP3TACR1
SCHEMBL1579320 0.82 POLB (0.57) TACR1EPHX2LMNACNR1
SCHEMBL4655121 0.79 LTA4H (0.59) BACE1BACE2NLRP3TACR1LTA4H
SCHEMBL30795667 0.77 GPR52 (0.55) EPHX2MRGPRX4RHOCRHOA
SCHEMBL1578844 0.77 GPR52 (0.55) EPHX2MRGPRX4RHOCRHOA
SCHEMBL1578975 0.75 MRGPRX4 (0.57) EPHX2MRGPRX4RHOCRHOA
SCHEMBL30794508 0.75 MRGPRX4 (0.57) EPHX2MRGPRX4RHOCRHOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2310357-B1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL AVIV UNIV LIMITED (IL) 2019-09-11 EP claimed
US-20160374969-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-12-29 US claimed
US-20110245250-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-10-06 US claimed
CN-102159535-A Potassium ion channel modulators and uses thereof UNIV RAMOT 2011-08-17 CN claimed
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed
US-20200308102-A1 MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2020-10-01 US disclosed
EP-2310357-B1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL AVIV UNIV LIMITED (IL) 2019-09-11 EP disclosed
EP-2310357-B1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL AVIV UNIV LIMITED (IL) 2019-09-11 EP disclosed
US-20160374969-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-12-29 US disclosed
US-9464052-B2 Potassium ion channel modulators and uses thereof RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-10-11 US disclosed
US-9464052-B2 Potassium ion channel modulators and uses thereof RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-10-11 US disclosed
US-9464052-B2 Potassium ion channel modulators and uses thereof RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-10-11 US disclosed
US-20110245250-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-10-06 US disclosed
US-20110245250-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-10-06 US disclosed
US-20110245250-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-10-06 US disclosed
CN-102159535-A Potassium ion channel modulators and uses thereof UNIV RAMOT 2011-08-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245250-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF SCN1B, KCNN3, SCN2B GLA 4573/4885BACE1 3653/4885BACE2 3870/4885
US-20160374969-A1 POTASSIUM ION CHANNEL MODULATORS & USES THEREOF KCNJ11, KCNJ1, KCNJ2 GLA 2443/4885BACE1 3623/4885BACE2 3437/4885
US-20200308102-A1 MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF TRPV1, TRPV2, TRPV5 GLA 2681/4885BACE1 2808/4885BACE2 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.